University of Iowa News
Sept. 23, 2005
UI Study Seeks Men Age 40 And Older With Overactive Bladder Problems
Men age 40 and older with overactive bladder problems are invited to participate in a University of Iowa research study of medications to treat symptoms.
The study will compare the safety and effectiveness of the investigational combination of two FDA-approved medications to use of placebo (inactive substance) in reducing symptoms.
Overactive bladder symptoms include taking more than eight trips to the bathroom in one day, strong and sudden urges to urinate and/or the inability to hold urine until getting to the toilet. Men with a history of interstitial cystitis or prostate cancer are not eligible to participate.
The study will involve approximately five visits to UI Hospitals and Clinics over 13 weeks. Participants will randomly be assigned to take one of the two study medications, both medications or a placebo. All participants will be asked to keep a voiding diary and complete several quality-of-life questionnaires about bladder health.
The study medication(s) and any urine and ultrasound tests will be provided at no cost. Compensation for clinic visits and parking is also available.
The University of Iowa is one of approximately 83 centers in the United States taking part in the study, which is funded by Pfizer.
The lead investigator is Karl Kreder, M.D., professor of urology in the UI Roy J. and Lucille A. Carver College of Medicine.
For more information, call the study coordinators at 319-384-5769 (Diane Meyerholz) or 319-384-9265 (Mary Eno). You may also e-mail the study coordinators at email@example.com or firstname.lastname@example.org.
STORY SOURCE: University of Iowa Health Science Relations, 5137 Westlawn, Iowa City, Iowa 52242-1178
Diane Meyerholz, study coordinator, 319-384-5769, email@example.com
Mary Eno, study coordinator, 319-384-9265, firstname.lastname@example.org
Media Only: Becky Soglin, 319-335-6660, email@example.com
NOTE: This announcement previously was released July 5, 2005. Participants still are welcomed to the study.